Hypersensitivity occurring on initial or subsequent treatment. AML; myelodysplastic syndrome, chronic myelogenous leukaemia, secondary AML; sickle cell trait or disease. Do not use to increase dose of cytotoxic chemotherapy beyond established dosage regimens. Discontinue in case of preliminary signs of acute resp distress syndrome (ARDS); leukocyte count >50 x 109
/L after expected nadir. Closely monitor patients who develop symptoms of capillary leak syndrome. Monitor urinalysis; spleen size; platelet count & haematocrit. Transient positive bone imaging findings. Latex-sensitive patients. Rare hereditary problems of fructose intolerance. Women of childbearing potential not using contraception. Pregnancy & lactation. Childn.